News Briefs: eMed refiles IPO, acquires Trilix
eMed refiles IPO, acquires TrilixeMed Technologies is moving ahead with plans to expand its portfolio of Internet-based products and services, fueled in large part by the prospect of a pending $46 million initial public offering. The Lexington,
eMed refiles IPO, acquires Trilix
eMed Technologies is moving ahead with plans to expand its portfolio of Internet-based products and services, fueled in large part by the prospect of a pending $46 million initial public offering. The Lexington, MA-based company originally filed for an IPO last August (PNN 9/99) but postponed the offering one month later, citing market volatility with regard to health-related IPOs (PNN 11/99). Apparently sensing a more positive climate on Wall Street these days, eMed refiled its IPO with the Securities and Exchange Commission Feb. 25.
In related news, eMed acquired Trilix Information Systems, a software company founded by several former Cemax-Icon engineers. Trilix, headquartered in Pleasanton, CA, provides integration technology that allows the exchange of information among different healthcare imaging and information systems, both within a hospitals network and via the Internet. The addition of Trilixs technology to eMeds image-management products and services should help facilitate an organizations move toward electronic medical records, providing clinicians with connectivity to diagnostic images, as well as to laboratory, pathology, and other diagnostic reports.
eMed also plans to make Trilixs interface technologies available to other vendors on an OEM basis. Trilix already has OEM relationships with Kodak and Canon, according to company sources. eMed acquired Trilix in a straight stock deal.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
